Health Economics›Gastrointestinal stromal tumor›Metastatic or unresectable disease second-line

Metastatic or unresectable disease second-line

Gastrointestinal stromal tumor · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Sunitinib monotherapy Variant #01	—	R 15 867	42d	8.3 mo	17.4 mo	2	R 31 733 PFS proxy	2
Linsitinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

2 of 2 regimens shown